Scientific Evidence

Clinical performance and management outcomes with the DecisionDx-UM gene expression profile test in a prospective multicenter study

Jun 2016

Uveal melanoma management is challenging due to its metastatic propensity. DecisionDx-UM is a prospectively validated molecular test that interrogates primary tumor biology to provide objective information about metastatic potential that can be used in determining appropriate patient care. To evaluate the continued clinical validity and utility of DecisionDx-UM, beginning March 2010, 70 patients were enrolled in a prospective, multicenter, IRB-approved study to document patient management differences and clinical outcomes associated with low-risk Class 1 and high-risk Class 2 results indicated by DecisionDx-UM testing.

Author: Plasseraud KM, et al.

Publication: Journal of Oncology

A tissue systems pathology assay for high-risk Barrett’s esophagus

May 2016

Exploration of a tissue systems pathology approach to predict progression in patients with non-dysplastic Barrett's esophagus.

Author: Critchley-Thorne RJ, et al.

Publication: Cancer Epidemiology, Biomarkers & Prevention

A tissue systems pathology test detects a field effect associated with high-grade dysplasia and esophageal cancer in Barrett’s esophagus patients

May 2016

TissueCypher better predicts the presence of HGD and EAC in BE than pathologic variables and can improve histology to identify patients requiring therapy.

Author: Critchley-Thorne RJ, et al.

Publication: Poster presentation (Sa1257) at DDW 2016, San Diego

Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients

May 2016

Post-test management plans were changed in 53% of patients who had risk aligned management changes concordant with a Class 1 (low risk) or Class 2 result (high risk).

Author: Berger A, et al.

Publication: Current Medical Research and Opinion

A cost-effectiveness analysis of a test that predicts risk of malignant progression in Barrett’s esophagus

May 2016

TissueCypher is cost-saving after five years and improves patient outcomes due to improving the effectiveness of surveillance and treatment.

Author: Hao J, et al.

Publication: Podium presentation (CN4) at ISPOR 2016, Washington DC

Uveal melanomas with SF3B1 mutations: a distinct subclass associated with late-onset metastases

May 2016

To investigate the prevalence and prognostic value of SF3B1 and EIF1AX mutations in uveal melanoma (UM) patients.

Author: Yavuzyigitoglu S, et al.

Publication: Ophthalmology

A cost-effectiveness analysis of a test that predicts risk of malignant progression in Barrett’s esophagus

May 2016

TissueCypher is cost-saving after five years and improves patient outcomes due to improving the effectiveness of surveillance and treatment.

Author: Hao J, et al.

Publication: Podium presentation (CN4) at ISPOR 2016, Washington DC

A tissue systems pathology test detects a field effect associated with high grade dysplasia and esophageal cancer in Barrett’s esophagus patients

May 2016

TissueCypher better predicts presence of HGD and EAC in BE than pathologic variables, and can improve on histology to identify patients requiring therapy.

Author: Critchley-Thorne RJ, et al.

Publication: Poster presentation (Sa1257) at DDW 2016, San Diego

Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma

Apr 2016

We analyzed genomics data from 136 uveal melanoma samples and found a recurrent mutation in CYSLTR2 (cysteinyl leukotriene receptor 2) encoding a p.Leu129Gln substitution in 4 of 9 samples that lacked mutations in GNAQGNA11, and PLCB4 but in 0 of 127 samples that harbored mutations in these genes. 

Author: Moore AR, et al.

Publication: Nature Genetics

A novel tissue systems pathology test predicts progression in Barrett’s esophagus patients

Apr 2016

TissueCypher better predicts progression in BE than clinicopathologic variables, and can improve on histology as a method to risk stratify patients with BE.

Author: Critchley-Thorne RJ, et al.

Publication: Podium presentation (301) at DDW 2016, San Diego

A cost-effectiveness analysis of a cancer risk prediction test for patients with Barrett’s esophagus

Apr 2016

The individualized risk prediction test has the potential to improve the efficiency of endoscopic surveillance in BE and to enable early intervention as needed.

Author: Hao J, et al.

Publication: Poster presentation (Sa 1261) at DDW 2016, San Diego

A cost-effectiveness analysis of a cancer risk prediction test for patients with Barrett’s esophagus

Apr 2016

The individualized risk prediction test has the potential to improve the efficiency of endoscopic surveillance in BE and to enable early intervention as needed.

Author: Hao J, et al.

Publication: Poster presentation (Sa1261) at DDW 2016, San Diego